49 years old woman with midgut carcinoid — case report

Abstract

The PROMID Study Group demonstrated the ability of somatostatin analogs to control not only in symptoms, bus also the growth of well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors (NETs). The presented case shows the efficacy of octreotide LAR not only in controlling the symptoms of the disease, but also in obtaining tumor size stabilization for 2 years. Moreover the biochemical and imaging investigations in the diagnosis of GI carcinoidshave been described, including the use of 24-hour urinary 5-hydroxyindoleacetic acid (5-HIAA) collection, chromogranina A and imaging — the use of somatostatin scintigraphy, computed tomography (CT). Although the definitive role of surgery in metastatic disease has not been established, resections of the intestine, mesenteric tumors may improve symptoms and quality of life substantially in patients with metastatic hepatic carcinoids.